{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001274","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.138382+00:00","generated_at":"2026-06-12T00:32:14.414435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agenus Q2 2023 net loss $73.4M; bot/bal combo mOS 20.9 months in CRC, FDA Fast Track","bullets":["Q2 revenue $25.3M, net loss $73.4M ($0.20 EPS); cash $157.6M at June 30, down from $193.4M at Dec 2022.","Bot/bal combo in 3L+ Non-MSI-H CRC: mOS 20.9 months vs 12.9 SOC; ORR 23% vs 2.8%; FDA Fast Track granted.","ACTIVATE Phase 2 CRC and melanoma trials on target to fully enroll by end of 2023; BLA submission planned in 2024.","AGEN2373 monotherapy shows clinical responses in prostate, ampullary, vulvar cancers; first CD137 agonist with no hepatic toxicity.","Leadership appointments: Robin Taylor (CCO), Homa Yeganegi (Chief Product Strategy & Global Medical Affairs), Stephanie Fagan (CCO)."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001274","json":"https://secwatch.observer/filing/0001157523-23-001274.json","markdown":"https://secwatch.observer/filing/0001157523-23-001274.md","text":"https://secwatch.observer/filing/0001157523-23-001274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000115752323001274/0001157523-23-001274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000115752323001274/a53512783.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:32:14.414435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}